Comment

Comment by suddenseizure

I've been following this field with great interest since my wife was diagnosed with brain cancer.

It seems many types of cancer can evolve resistance to treatment with a single type of immunotherapy. Similar to how HIV quickly evolved resistance to treatment by one ARV (antiretroviral).

But HIV can be kept in check by a cocktail of 3 ARVs simultaneously. And there's some recent research from Mass General where they managed to eradicate brain tumors in mice using 3 different immunotherapies simultaneously: https://advances.massgeneral.org/neuro/journal.aspx?id=1263

> Dr. Curry's group describes "a likely oversimplified, but reasonable" summary of the mechanism of the triple therapy: GVAX expands the number and diversity of activated tumor-specific T cells and increases the number of intratumor CD8+ T cells, while PD-1 inhibition further invigorates the effects of those mobilized cells. Meanwhile, agonist anti-OX40 continues to skew systemic and tumor microenvironments toward Th1 immunity, suppress regulatory T cells and prevent T cell exhaustion.

Hopefully this is a way forward for treating humans too!

Discussion

Live from the official Hacker News API

A modern reader for Hacker News · SvelteKit + Skeleton